These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22476041)

  • 1. Obesity-independent association of human adenovirus Ad37 seropositivity with nonalcoholic fatty liver disease.
    Trovato GM; Martines GF; Pirri C; Trovato FM; Castro A; Garozzo A; Catalano D
    J Clin Gastroenterol; 2012 Jul; 46(6):e46-54. PubMed ID: 22476041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease.
    Trovato GM; Martines GF; Garozzo A; Tonzuso A; Timpanaro R; Pirri C; Trovato FM; Catalano D
    Liver Int; 2010 Feb; 30(2):184-90. PubMed ID: 19840251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance.
    Trovato GM; Martines GF; Trovato FM; Pirri C; Pace P; Garozzo A; Castro A; Catalano D
    Dig Dis Sci; 2012 Feb; 57(2):535-44. PubMed ID: 21953137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of nondiabetic Korean adults.
    Sung KC; Ryan MC; Kim BS; Cho YK; Kim BI; Reaven GM
    Diabetes Care; 2007 Aug; 30(8):2113-8. PubMed ID: 17475935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.
    Kim HJ; Kim HJ; Lee KE; Kim DJ; Kim SK; Ahn CW; Lim SK; Kim KR; Lee HC; Huh KB; Cha BS
    Arch Intern Med; 2004 Oct; 164(19):2169-75. PubMed ID: 15505132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human obesity relationship with Ad36 adenovirus and insulin resistance.
    Trovato GM; Castro A; Tonzuso A; Garozzo A; Martines GF; Pirri C; Trovato F; Catalano D
    Int J Obes (Lond); 2009 Dec; 33(12):1402-9. PubMed ID: 19786969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADV36 adipogenic adenovirus in human liver disease.
    Trovato FM; Catalano D; Garozzo A; Martines GF; Pirri C; Trovato GM
    World J Gastroenterol; 2014 Oct; 20(40):14706-16. PubMed ID: 25356033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or =95th percentile.
    Quirós-Tejeira RE; Rivera CA; Ziba TT; Mehta N; Smith CW; Butte NF
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):228-36. PubMed ID: 17255837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study.
    Moscatiello S; Di Luzio R; Bugianesi E; Suppini A; Hickman IJ; Di Domizio S; Dalle Grave R; Marchesini G
    Obesity (Silver Spring); 2011 Apr; 19(4):763-70. PubMed ID: 20966900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase.
    López-Suárez A; Guerrero JM; Elvira-González J; Beltrán-Robles M; Cañas-Hormigo F; Bascuñana-Quirell A
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1011-7. PubMed ID: 21915061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease.
    Church TS; Kuk JL; Ross R; Priest EL; Biltoft E; Blair SN
    Gastroenterology; 2006 Jun; 130(7):2023-30. PubMed ID: 16762625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.
    Fracanzani AL; Valenti L; Bugianesi E; Vanni E; Grieco A; Miele L; Consonni D; Fatta E; Lombardi R; Marchesini G; Fargion S
    J Hepatol; 2011 Jun; 54(6):1244-9. PubMed ID: 21145841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-alcoholic fatty liver disease and its association with clinical and biochemical variables in obese children and adolescents: effect of a one-year intervention on lifestyle].
    Santomauro M; Paoli-Valeri M; Fernández M; Camacho N; Molina Z; Cicchetti R; Valeri L; Dávila de Campagnaro E; Arata-Bellabarba G
    Endocrinol Nutr; 2012; 59(6):346-53. PubMed ID: 22717644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.
    Musso G; Gambino R; Bo S; Uberti B; Biroli G; Pagano G; Cassader M
    Diabetes Care; 2008 Mar; 31(3):562-8. PubMed ID: 18056890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy.
    Shieh K; Gilchrist JM; Promrat K
    Muscle Nerve; 2010 Feb; 41(2):197-201. PubMed ID: 19813185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions.
    Trovato FM; Catalano D; Martines GF; Pace P; Trovato GM
    Clin Nutr; 2015 Feb; 34(1):86-8. PubMed ID: 24529325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
    Marchesini G; Bugianesi E; Forlani G; Cerrelli F; Lenzi M; Manini R; Natale S; Vanni E; Villanova N; Melchionda N; Rizzetto M
    Hepatology; 2003 Apr; 37(4):917-23. PubMed ID: 12668987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H; Moschen A
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.